IDEXX Laboratories, Inc.
IDEXX Laboratories is a leading provider of diagnostic tests, instruments and software for the animal health and water testing markets. The company sells a mix of instruments and high-margin consumables as well as practice-management and diagnostic software that together create recurring revenue streams and close customer relationships with veterinary clinics and laboratories. IDEXX benefits from structural trends such as rising pet ownership and increased spending on companion animal care, while also operating in water and livestock testing markets. Investors should note it is exposed to competitive pressures, regulatory requirements and technological change, and its performance can vary with regional veterinary spending and currency moves. The company’s market cap (around $51 billion) reflects sizeable scale and long-term growth expectations, but this is general information only and not personal financial advice — suitability depends on your goals, risk tolerance and timeframe.
Why It's Moving
IDEXX Powers Ahead on Surging Vet Diagnostics Demand After Stellar Q3 Beat.
IDEXX Laboratories crushed Q3 2025 expectations with 13% revenue growth and 21% EPS surge, fueled by booming companion animal diagnostics and innovative product adoption. The company raised its full-year outlook, signaling robust momentum in pet healthcare amid rising clinical needs.
- Q3 revenue hit record highs with 13% reported growth to over $1.1B, driven by 11% rise in CAG Diagnostics recurring revenue from higher testing volumes and premium instrument placements[2][3].
- EPS jumped 21% to $3.40, beating estimates by 8.3%, with operating margins expanding to 32.1% on strong execution and innovations like IDEXX inVue Dx and Cancer Dx[2][3].
- Upped 2025 revenue guidance to $4,270-$4,300M and flagged rising clinical demand, reinforced by Barclays' fresh Overweight rating with $850 target[2][3][8].
IDEXX Powers Ahead on Surging Vet Diagnostics Demand After Stellar Q3 Beat.
IDEXX Laboratories crushed Q3 2025 expectations with 13% revenue growth and 21% EPS surge, fueled by booming companion animal diagnostics and innovative product adoption. The company raised its full-year outlook, signaling robust momentum in pet healthcare amid rising clinical needs.
- Q3 revenue hit record highs with 13% reported growth to over $1.1B, driven by 11% rise in CAG Diagnostics recurring revenue from higher testing volumes and premium instrument placements[2][3].
- EPS jumped 21% to $3.40, beating estimates by 8.3%, with operating margins expanding to 32.1% on strong execution and innovations like IDEXX inVue Dx and Cancer Dx[2][3].
- Upped 2025 revenue guidance to $4,270-$4,300M and flagged rising clinical demand, reinforced by Barclays' fresh Overweight rating with $850 target[2][3][8].
Stock Performance Snapshot
Analyst Rating
Analysts recommend buying IDEXX Laboratories' stock with a target price of $771.46, showing growth potential.
Financial Health
IDEXX Laboratories is generating strong revenue and cash flow, indicating good financial performance overall.
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Baskets Featuring IDXX
Activist Sparks Life Science Shakeup
Activist investor Engine Capital is pushing for a sale of life-sciences company Avantor after taking a significant stake. This move could spark a wave of M&A across the life-sciences supply industry, creating opportunities for competitor firms and other potential acquisition targets.
Published: August 11, 2025
Explore BasketPets Are Family
The emotional bond with our furry companions has created a powerful, recession-resistant market. These carefully selected companies provide essential veterinary care, nutrition, and wellness services that pet owners prioritize regardless of economic conditions.
Published: June 17, 2025
Explore BasketWhy You’ll Want to Watch This Stock
Steady Consumables Demand
High-margin consumables and recurring test volumes can support predictable revenue, though demand may fluctuate with vet clinic activity.
Global Pet Care Trends
Growing pet ownership and higher veterinary spending provide long-term tailwinds, while international expansion adds opportunity and exposure to currency risk.
Innovation & Software
Diagnostics instruments and practice-management software help differentiate the offering, yet product cycles and competition create execution risk.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
6% Interest on Cash
Earn 6% AER on uninvested cash with daily interest payments.
Discover More Opportunities
Abbott Laboratories
Abbott Laboratories is a global healthcare company that develops and markets a broad range of health care products, including medical devices, diagnostics, nutritionals, and branded generic pharmaceuticals.
Agilent Technologies Inc.
Agilent Technologies, Inc. specializes in life sciences, diagnostics and applied markets, providing application-focused solutions that include instruments, software, services and consumables for the entire laboratory workflow. Its segments include Life Sciences and Diagnostics Markets, Agilent CrossLab and Applied Markets. Life Sciences and Diagnostics Markets segment comprises seven areas of activity. It offers active pharmaceutical ingredients for oligo-based therapeutics as well as solutions that include reagents, instruments, software and consumables. Agilent CrossLab segment offers a services and consumables portfolio that spans the entire lab, in addition to software and laboratory automation solutions, which are designed to enhance customer outcomes. Applied Markets segment offers application-focused solutions that include instruments and software that enable customers to identify, quantify and analyze the physical and biological properties of substances and products.
Align Technology Inc.
Align Technology is a medical device company that designs, manufactures and markets a range of dental and orthodontic products.
